

## PurifLOH Limited

ABN: 11 124 426 339

**Reporting Period:** For the year ended 30 June 2021

**Previous Period:** For the year ended 30 June 2020

### Principal Activities and Review of Operations

Results for Announcement to Market	\$ Change	% Change	12 months to 30 June 2021 \$	12 months to 30 June 2020 \$
Revenue from ordinary activities	Nil	0%	Nil	Nil
Profit/(loss) after tax from ordinary activities attributable to members	1,440,054	(31.8%)	(3,087,981)	(4,528,035)
Profit/(loss) attributable to members	1,440,054	(31.8%)	(3,087,981)	(4,528,035)

Earnings Per Share	30 June 2021 Cents	30 June 2020 Cents
Basic loss per share - weighted average	(9.796)	(14.389)
Diluted loss per share - weighted average	(9.796)	(14.389)

Dividend Information	Amount per share	Franked Amount per share
Dividend – current reporting period	Nil	Nil
Dividend – previous reporting period	Nil	Nil

Net Tangible Asset Backing per Ordinary Share	Cents
Net tangible asset backing per ordinary share – current reporting period	(3.39)
Net tangible asset backing per ordinary share – previous reporting period	4.42

### Commentary on the Results for the Period

The loss results from normal operating expenses of the company associated with its ongoing research and development program at Somnio Group International Limited in the USA for the Free Radical Generator.

### Attachments

The following documents are attached:

- Explanation of Principal Activities and Review of Operations
- The Preliminary Final Report of PurifLOH Limited for the year ended 30 June 2021

## Audit Status

This Preliminary Final Report is based on the Annual Financial Report which is yet to be audited.

The audit is not yet at a stage where it is possible for the Directors to anticipate whether the independent audit report will be subject to a modified, emphasis of matter or other matter paragraph.

## Control gained over entities

None

## Loss of control over entities

None

## Current period

There were no dividends paid, recommended or declared during the current year.

## Previous period

There were no dividends paid, recommended or declared during the previous period

## Dividend reinvestment plans

None

## Details of associates and joint venture entities

None

## Foreign entities

None

## Any other significant information

The Group may elect to enact ASIC lodgement date extensions available to it (per ASIC Media Release, 21-082MR) for the release of its annual report in the current year. Should the extension be utilised, the Group will be permitted an extra month to complete and have audited, its annual report for lodgement by 31 October 2021. The extended deadlines will assist pressures on resources for the audit process for smaller entities and provide adequate time for the completion of the audit process taking into account challenges presented by COVID-19 conditions, including audit firm resources.



Simon Lill  
Executive Director

Dated at Perth this 31st day of August 2021

PuriflOH Limited (“PuriflOH”, “PO3” or “Company”) has continued to develop the Free Radical Generator (“FRG”) through Somnio Group Holdings Limited. During the year the Company commenced to bring the commercialisation activities back to Australia where it is pleased to note the ongoing launch of two products, being:

1. The Air Conditioning Environmental Remediation Treatment (“ACERT”); and
2. The whole of room air purifier (“WRAP”).

Through the period the Company also announced development relationships with Aspen Medical Limited and Osmoflo Limited, leaders in their respective fields of healthcare solutions and water treatment. The Company sees both of these arrangements as significant steps forward in its product commercialisation.

During the year two directors of the Company, Mr. William (Bill) Parfet and Professor Pravansu Mohanty both resigned in keeping with the Company’s moves to a more Australian focussed company. The directors were replaced by Mr. Jonathon (Jon) Evans (Operational) and Dr. Alex Sava (Technical).

PuriflOH has also advised of ongoing R&D being undertaken on behalf of a global OEM which it expects to report on during the forthcoming quarter.

The Company has placed its initial orders of FRG units and has commenced its deployment of same.

The Company enjoys the ongoing financial support of its key shareholder, Dilato Holdings Pty Limited as evidenced by the further financing facility that was put in place for \$1M during the year, and of which \$200,000 was recently drawn down. The Company is also adjusting its relationship with the Somnio Group to reduce expenditure. The Company is conscious of capital requirements and consistently examines the various options available to the Company in this respect.

**PURIFLOH LIMITED**  
**Preliminary Final Report**  
**30 June 2021**

**General Information**

The financial statements cover PurifLOH Limited. They are presented in Australian dollars, which is PurifLOH Limited's functional and presentation currency.

The preliminary financial statements were authorised for issue, in accordance with a resolution of directors, on 31 August 2021. The directors have the power to amend and reissue the financial statements.

For personal use only

**CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME**

For the 12 months ended 30 June 2021

	Note	30 June 2021 \$	30 June 2020 \$
<b>Revenue</b>			
Revenue from continuing operations		-	-
<b>Other Income</b>			
Interest income		17	56,541
Realised FX Gain		-	108,160
Unrealised FX Gain		-	77,334
<b>Total Other Income</b>		<b>17</b>	<b>242,035</b>
Research and Development – Somnio		(1,080,184)	(3,625,645)
General and Admin – Somnio		(131,177)	(358,950)
Accounting and audit		(165,810)	(167,301)
Other Expenses		(983,476)	(617,791)
Finance costs		(3,876)	(383)
Realised FX Loss		(81,305)	-
Unrealised FX Loss		(642,170)	-
<b>Total expense</b>		<b>(3,087,998)</b>	<b>(4,770,070)</b>
<b>Profit/(Loss) before income tax</b>		<b>(3,087,981)</b>	<b>(4,528,035)</b>
Income tax expense		-	-
<b>Net Profit/(Loss) for the period</b>		<b>(3,087,981)</b>	<b>(4,528,035)</b>
<b>Other Comprehensive Income</b>			
<b>Items that may be reclassified to profit or loss</b>			
Exchange differences on translating foreign operations		627,715	31,182
<b>Total Comprehensive Income/(Loss) for the period</b>		<b>(2,460,266)</b>	<b>(4,496,853)</b>
<b>Attributable to owners of the parent entity</b>		<b>(2,460,266)</b>	<b>(4,496,853)</b>
Basic earnings Profit/(loss) per share (cents)		(9.796)	(14.389)
Diluted earnings Profit/(loss) per share (cents)		(9.796)	(14.389)

The Statement of Comprehensive Income above should be read in conjunction with the accompanying notes.

**CONSOLIDATED STATEMENT OF FINANCIAL POSITION**

As at 30 June 2021

	30 June 2021 \$	30 June 2020 \$
<b>Assets</b>		
<b>Current Assets</b>		
Cash and cash equivalents	30,218	2,355,557
Trade and other receivables	24,871	8,250
Prepayments	17,609	14,297
<b>Total Current Assets</b>	<b>72,689</b>	<b>2,378,104</b>
<b>Non-Current Assets</b>		
Intangible assets - trade marks	67,555	62,528
<b>Total Non-Current Assets</b>	<b>67,555</b>	<b>62,528</b>
<b>Total Assets</b>	<b>140,253</b>	<b>2,440,632</b>
<b>Liabilities</b>		
<b>Current Liabilities</b>		
Trade and other payables	1,056,594	1,048,296
Borrowings - Dilato	151,589	-
<b>Total Current Liabilities</b>	<b>1,208,183</b>	<b>1,048,296</b>
<b>Total Liabilities</b>	<b>1,208,183</b>	<b>1,048,296</b>
<b>Net Assets/(Liabilities)</b>	<b>(1,067,930)</b>	<b>1,392,336</b>
<b>Equity/ (Shareholders' Deficit)</b>		
Contributed equity	84,352,846	84,352,846
Foreign exchange translation reserve	634,308	6,593
Accumulated losses	(86,055,084)	(82,967,103)
<b>Total Equity/ (Shareholders' Deficit)</b>	<b>(1,067,930)</b>	<b>1,392,336</b>

The Statement of Financial Position above should be read in conjunction with the accompanying notes.

**CONSOLIDATED STATEMENT OF CHANGES IN EQUITY**

For the 12 months ended 30 June 2021

	Contributed Equity	Foreign Currency Translation Reserve	Accumulated losses	Total
	\$	\$	\$	\$
<b>Balance at 1 July 2020</b>	<b>84,352,846</b>	<b>6,593</b>	<b>(82,967,103)</b>	<b>1,392,336</b>
Profit/(Loss) for the period	-	-	(3,087,981)	(3,087,981)
Other comprehensive income	-	627,715	-	627,715
<b>Total comprehensive income (loss) for the period</b>	<b>-</b>	<b>627,715</b>	<b>(3,087,981)</b>	<b>(2,460,266)</b>
<b>Equity Transactions</b>				
Issue of shares during the year	-	-	-	-
Transaction costs net of tax	-	-	-	-
Share conversion	-	-	-	-
<b>Balance at 30 June 2021</b>	<b>84,352,846</b>	<b>634,308</b>	<b>(86,055,084)</b>	<b>(1,067,930)</b>

For the 12 months ended 30 June 2020

	Contributed Equity	Foreign Currency Translation Reserve	Accumulated losses	Total
	\$	\$	\$	\$
<b>Balance at 1 July 2019</b>	<b>83,961,448</b>	<b>(24,589)</b>	<b>(78,439,068)</b>	<b>5,497,791</b>
Profit/(Loss) for the period	-	-	(4,528,035)	(4,528,035)
Other comprehensive income	-	31,182	-	31,182
<b>Total comprehensive income (loss) for the period</b>	<b>-</b>	<b>31,182</b>	<b>(4,528,035)</b>	<b>(4,496,853)</b>
<b>Equity Transactions</b>				
Issue of shares during the year	391,398	-	-	391,398
Transaction costs net of tax	-	-	-	-
Share conversion	-	-	-	-
<b>Balance at 30 June 2020</b>	<b>84,352,846</b>	<b>6,593</b>	<b>(82,967,103)</b>	<b>1,392,336</b>

The Statement of Changes in Equity above should be read in conjunction with the accompanying notes.

**CONSOLIDATED STATEMENT OF CASH FLOWS**

For 12 months ended 30 June 2021

	30 June 2021 \$	30 June 2020 \$
<b>Cash flows related to operating activities</b>		
Interest Received	17	56,541
Payments for research and development and other working capital	(2,370,256)	(4,033,673)
<b>Net operating cash flows</b>	<b>(2,370,239)</b>	<b>(3,977,132)</b>
<b>Cash flows related to investing activities</b>		
Purchase of intangibles	(9,210)	(2,188)
<b>Net investing cash flows</b>	<b>(9,210)</b>	<b>(2,188)</b>
<b>Cash flows related to financing activities</b>		
Proceeds from borrowings	151,589	-
<b>Net financing cash flows</b>	<b>151,589</b>	<b>-</b>
Net increase / (decrease) in cash held	(2,227,860)	(3,979,320)
Net foreign exchange differences	(97,479)	31,182
Cash and cash equivalents at beginning of the period	2,355,557	6,303,695
<b>Cash and Cash Equivalents at the end of the period</b>	<b>30,218</b>	<b>2,355,557</b>

The Statement of Cash Flows above should be read in conjunction with the accompanying notes.



## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

### 1. General Information

PuriflOH Limited (“PuriflOH”, “the Company” or “PO3”) is a public company, incorporated and domiciled in Australia. The Company listed on the Australian Securities Exchange (ASX) on 30 December 2010.

#### Basis of Preparation – Accounting policies, estimation methods and measurement bases

These preliminary statements have been prepared in accordance with the ASX listing rules and do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the financial statements for the year ended 30 June 2020 and any public announcements made by the company during the reporting period in accordance with continuous disclosure requirements of the *Corporations Act 2001*.

Accounting policies, estimation methods and measurement bases used in this Appendix 4E are the same as those used in the last annual report and the last half-year report.

#### Going Concern

This financial report has been prepared on a going concern basis, which contemplates the continuity of normal business activities and realisation of assets and discharge of liabilities in the ordinary course of business.

The group incurred an operating loss after tax for the year of \$3,087,981, net cash outflows from operating activities of \$2,370,239 and a deficiency in net current assets of \$1,135,494 as at 30 June 2021.

Notwithstanding the above, the continuation of the Group as a going concern is dependent upon its ability to achieve the following:

- The continued financial support from the Dilato loan facility, which remains available to the Group with a further \$200,000 received subsequent to balance date;
- The continued support of creditors;
- The ability to raise additional capital or attract alternate sources of funding; and
- The generation of cash inflows resulting from successful engagement with OEM’s.

The Directors have reviewed the business outlook and the assets and liabilities of the Group and are of the opinion that despite the above, the Group has implemented strategies to ensure there is sufficient funding for at least the next 12 months.

### 2. Significant Events after Balance Sheet Date

There have been no significant events since the balance date.

### 3. Interests in Subsidiaries

The consolidated financial statements include the financial statements of PuriflOH and its subsidiaries listed in the following table:

Name	Country of Incorporation	Equity Interest	
		2021	2020
PuriflOH USA Incorporated	United States	100%	100%

The Company has a US subsidiary called PuriflOH USA Incorporated. This subsidiary was incorporated in Delaware, USA in late 2018. The subsidiary carries a subscription of shares of common stock with par value of US\$0.001 of which PuriflOH Limited owns 100%. As a result of this establishment, the financial statements reflect the consolidation position of the parent and the subsidiary collectively as the Group.

The purpose of this entity is to manage operations in the US as the Company moves forward with its commercialization plans for the Free Radical Generator. The Company has noted the change to operational focus to return to Australia, however deems it important to retain the US subsidiary as there are many ongoing facets of commercialisation within the United States.